Molecular Basis of Angiopathy in Diabetes Mellitus
2006; Lippincott Williams & Wilkins; Volume: 98; Issue: 1 Linguagem: Inglês
10.1161/01.res.0000200396.90220.41
ISSN1524-4571
AutoresJean‐Sébastien Silvestre, Bernard Lévy,
Tópico(s)Cerebrovascular and Carotid Artery Diseases
ResumoHomeCirculation ResearchVol. 98, No. 1Molecular Basis of Angiopathy in Diabetes Mellitus Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBMolecular Basis of Angiopathy in Diabetes Mellitus Jean-Sébastien Silvestre and Bernard I. Lévy Jean-Sébastien SilvestreJean-Sébastien Silvestre From the Centre for Cardiovascular Research Lariboisière; INSERM Unit 689, Paris, France. and Bernard I. LévyBernard I. Lévy From the Centre for Cardiovascular Research Lariboisière; INSERM Unit 689, Paris, France. Originally published6 Jan 2006https://doi.org/10.1161/01.RES.0000200396.90220.41Circulation Research. 2006;98:4–6Cardiovascular complications are the leading cause of morbidity and mortality in patients with diabetes mellitus; up to 80% of deaths in patients with diabetes are closely associated with vascular disease. The ability of the organism to form a collateral network of blood vessels constitutes an important response to vascular occlusive disease and determines to a large part the clinical consequences and severity of tissue ischemia. The development of new vessels is significantly reduced in diabetic patients with coronary or peripheral artery disease.1,2 This probably contributes to the severe course of limb ischemia in diabetic patients, in which peripheral artery disease often results in foot ulceration and lower extremity amputation.Diabetic retinopathy remains one of the major causes of acquired blindness in developed nations. This is true despite the development of laser treatment, which can prevent blindness in the majority of those who develop macular edema or proliferative diabetic retinopathy. The hallmark of diabetic retinopathy is the lack of microvessels in the macula, leading to hypoxia, associated with peripheral retinal neovascularization that may ultimately cause severe vitreous cavity bleeding and/or retinal detachment. The factors that stimulate retinal blood vessel growth have not been fully defined, but there is accumulating evidence that the renin-angiotensin-bradykinin system (RAKS) may be involved in a number of retinal vascular disorders, including retinopathy of prematurity and proliferative diabetic retinopathy3,4Only a few studies have specifically evaluated the effect of diabetes on angiogenesis in ischemic vascular disease and in the retina. Moreover, the mechanisms by which diabetes could both limit the formation of new blood vessels in most organs and simultaneously induce proliferative diabetic retinopathy remain largely undefined.Main Molecular Mechanisms of Ischemia-Induced NeovascularizationAfter acute ischemia, hypoxia and inflammation are believed to be the major stimuli causing neovascularization.5 Cells exposed to hypoxia respond by increasing the level of hypoxia-inducible factor-1 (HIF-1). This factor then activates a number of genes by binding to hypoxia response elements in their promoter regions. A second hypoxia-responsive factor, HIF-2, can activate many of the same genes as HIF-1, such as the vascular endothelial growth factor (VEGF).6 VEGF is a major proangiogenic factor activating phosphatidylinositol-3′-kinase/Akt and thus the cell survival, migration, and proliferation.7 Akt has been shown to phosphorylate endothelial nitric oxide synthase (eNOS) leading to a persistent calcium-independent enzyme activation and enhanced endothelial NO synthesis and thereby influences the long-term regulation of vessel growth. A large body of literature indicates an essential role of endothelial NO for postnatal neovascularization.8 The downstream effector pathways, by which NO mediates its effects, are less clear but may involve integrin-linked signal transduction processes.Inflammatory processes are also necessary in the ischemia-induced neovascularization process. Activated monocytes and macrophages have been evidenced in ischemic tissues; these cells adhere to the vascular wall during angiogenesis and activate the production of both proangiogenic cytokines such as basic fibroblast growth factor (bFGF), VEGF, IL-18 binding protein, tumor necrosis factor (TNF)-α, and matrix metalloproteinases (MMPs), a family of enzymes that proteolytically degrade various components of the extracellular matrix.9–12Ischemia-induced neovascularization also involves circulating vascular progenitor stem cells. After tissue ischemia, progenitor endothelial cells are mobilized from the bone marrow to the blood stream, and then home to ischemic tissues where they promote neovascularization through the paracrine production of growth factors and possible also by incorporation into neovessels.13–15Impaired Ischemia-Induced Neovascularization in DiabetesIn diabetic patients, collateralization and angiogenesis are insufficient to overcome the loss of blood flow through narrowed or occluded arteries leading to ischemia and often nontraumatic limb amputation. However, only few studies have focused on the identification of factors that may affect neovascularization in the setting of ischemia in diabetes. It has been suggested that alteration in VEGF expression and signalization participate to neovascularization abnormalities in diabetes mellitus.2 Attenuation of the ability of monocytes to migrate has also been reported in diabetic patients because of a downstream signal transduction defect. The abrogation of the resulting inflammatory reaction might be critical to the formation of new blood vessels in this context.16 Increased formation of advanced glycation end-products (AGEs) is also regarded as one of the main mechanisms responsible for vascular damage in patients with diabetes. Glycation of extracellular matrix is a consequence of prolonged elevated glucose levels that react with proteins by a nonenzymatic posttranslational modification process called nonenzymatic glycation. This process is purely adventitious and therefore is likely to be more important in proteins possessing a long biological half-life such as collagen.17 In experimental models of diabetes, the ability to inhibit these pathways prevented diabetic retinopathy.18 AGE formation has also been shown to reduce the proteolysis of the glycated proteins and therefore may affect the angiogenic reaction. Hence, pharmacological inhibition of AGE formation is able to restore the ischemia-induced revascularization process in mice hindlimb.19 Finally, reduction in the mobilization, differentiation, and incorporation of endothelial progenitor cells at the level of the neo-vessels might participate to the angiogenic deficit in a diabetic context. In a diabetic type-1 mouse model, it has been reported that the ability of bone marrow mononuclear cells to differentiate into endothelial progenitor cells was strongly affected, resulting in reduced proangiogenic potential.20 In the same way, EPCs from type-1 or -2 diabetic patients evidenced a impaired proliferation and adhesion and incorporation into vascular structures, supporting the hypothesis of altered EPCs in diabetes21,22Tanii et al23 in this issue of Circulation Research used a model of severe hind limb ischemia to further investigate the mechanisms of microangiopathy in streptozotocin-induced diabetic mice (STZ-DM). Diabetic mice frequently lost their hind limbs at various levels after ischemia, whereas the nondiabetic mice did not. The authors showed a disturbance of the PDGF-BB/PKC axis, but not of impaired expression or efficiency of angiogenic factors. Hence, VEGF-A, VEGF-C, HGF, FGF-1, PDGF-A, and their receptors flk-1, flt-1, PDGFRα, and -β gene expression were unaffected in STZ-DM. In addition, FGF-2 gene transfer resulted in the upregulation of endogenous VEGF and HGF, prevented limb amputation, and restored limb blood flow, suggesting that angiogenic responses were minimally impaired in the STZ-DM model. In contrast, the PDGF-B expression was reduced in the STZ-DM in correlation with AGEs accumulation and morphological abnormalities of newly formed capillaries (dissociation of pericytes from the capillaries in ischemic muscles). Supplementation of the PDGF-B gene expression and PKC inhibitors restored the tissue levels of PDGF-B and were effective in preventing auto-amputation (Figure). Many questions remain unanswered. Is PKC/PDGF-BB axis affected in other models of diabetes; how does a 50% reduction in PDGF-BB expression lead to pericytes dissociation; and what is the nature of the intracellular signaling involved in PKC-induced downregulation of PDGF-BB gene expression? How does an alteration in the expression of a single growth factor can induced abnormalities in neovascularization? With a disease as complex as diabetes, other factors are likely to be involved as well. However, these results strongly suggest that defects and impairments in the main proangiogenic factors are not obligatorily involved in the complication of severe ischemia occurring in this model of STZ-induced diabetes. In addition, the PKC/PDGF-BB axis could be a new molecular target for treating severe ischemic peripheral lesions in patients with diabetic complications.Download figureDownload PowerPointGraphical representation of the proposed mechanisms leading to neovascularization abnormalities in diabetes mellitus. Diabetes-induced AGE accumulation promotes PKC activation and subsequent reduction in PDGF-BB gene expression. At the same time, AGEs hamper extracellular matrix degradation. Supplementation of the PDGF-B gene expression and PKC inhibitors restored the tissue levels of PDGF-B and are effective in increasing neovascularization and preventing auto-amputation in diabetic mice.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.B.L. and J.S.S. are supported by grants from INSERM and University Paris 7.FootnotesCorrespondence to Bernard I. Lévy, Centre for Cardiovascular Research Lariboisière; INSERM Unit 689, 41 Bd de la Chapelle, 75475 Paris Cedex 10, France. E-mail: [email protected] References 1 Abaci A, Oguzhan A, Kahraman S, Eryol NK, Unal S, Arinc H, Ergin A. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation. 1999; 99: 2239–2242.CrossrefMedlineGoogle Scholar2 Rivard A, Silver M, Chen D, Kearney M, Magner M, Annex B, Peters K, Isner JM. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol. 1999; 154: 355–363.CrossrefMedlineGoogle Scholar3 Sarlos S, Rizkalla B, Moravski CJ, Cao Z, Cooper ME, Wilkinson-Berka JL. Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. Am J Pathol. 2003; 163: 879–887.CrossrefMedlineGoogle Scholar4 Moravski CJ, Kelly DJ, Cooper ME, Gilbert RE, Bertram JF, Shahinfar S, Skinner SL, Wilkinson-Berka JL. Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension. 2000; 36: 1099–1104.CrossrefMedlineGoogle Scholar5 Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003; 9: 653–660.CrossrefMedlineGoogle Scholar6 Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992; 359: 843–845.CrossrefMedlineGoogle Scholar7 Dimmeler S, Zeiher AM. Akt takes center stage in angiogenesis signaling. Circ Res. 2000; 86: 4–5.CrossrefMedlineGoogle Scholar8 Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C, Kearney M, Chen D, Symes JF, Fishman MC, Huang PL, Isner JM. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest. 1998; 101: 2567–2578.CrossrefMedlineGoogle Scholar9 Arras M, Ito WD, Scholz D, Winkler B, Schaper J, Schaper W. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin Invest. 1998; 101: 40–50.CrossrefMedlineGoogle Scholar10 Ito WD, Arras M, Winkler B, Scholz D, Schaper J, Schaper W. Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion. Circ Res. 1997; 80: 829–837.CrossrefMedlineGoogle Scholar11 Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med. 2005; 9: 267–285.CrossrefMedlineGoogle Scholar12 Mallat Z, Silvestre JS, Le Ricousse-Roussanne S, Lecomte-Raclet L, Corbaz A, Clergue M, Duriez M, Barateau V, Akira S, Tedgui A, Tobelem G, Chvatchko Y, Levy BI. Interleukin-18/interleukin-18 binding protein signaling modulates ischemia-induced neovascularization in mice hindlimb. Circ Res. 2002; 91: 441–448.LinkGoogle Scholar13 Shintani S, Murohara T, Ikeda H, Ueno T, Honma T, Katoh A, Sasaki Ki, Shimada T, Oike Y, Imaizumi T. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation. 2001; 103: 2776–2779.CrossrefMedlineGoogle Scholar14 Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999; 85: 221–228.CrossrefMedlineGoogle Scholar15 Crosby JR, Kaminski WE, Schatteman G, Martin PJ, Raines EW, Seifert RA, Bowen-Pope DF. Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ Res. 2000; 87: 728–730.CrossrefMedlineGoogle Scholar16 Waltenberger J, Lange J, Kranz A. Vascular endothelial growth factor-A-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus. a potential predictor for the individual capacity to develop collaterals. Circulation. 2000; 102: 185–190.CrossrefMedlineGoogle Scholar17 Paul RG, Bailey AJ. Glycation of collagen: the basis of its central role in the late complications of ageing and diabetes. Int J Biochem Cell Biol. 1996; 28: 1297–1310.CrossrefMedlineGoogle Scholar18 Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee M. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med. 2003; 9: 294–299.CrossrefMedlineGoogle Scholar19 Tamarat R, Silvestre JS, Huijberts M, Benessiano J, Ebrahimian TG, Duriez M, Wautier MP, Wautier JL, Levy BI. Blockade of advanced glycation end-product formation restores ischemia-induced angiogenesis in diabetic mice. Proc Natl Acad Sci U S A. 2003; 100: 8555–8560.CrossrefMedlineGoogle Scholar20 Tamarat R, Silvestre JS, Le Ricousse-Roussanne S, Barateau V, Lecomte-Raclet L, Clergue M, Duriez M, Tobelem G, Levy BI. Impairment in ischemia-induced neovascularization in diabetes: bone marrow mononuclear cell dysfunction and therapeutic potential of placenta growth factor treatment. Am J Pathol. 2004; 164: 457–466.CrossrefMedlineGoogle Scholar21 Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, Levine JP, Gurtner GC. Related Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation. 2002; 106: 2781–2786.LinkGoogle Scholar22 Loomans CJ, de Koning EJ, Staal FJ, Rookmaaker MB, Verseyden C, de Boer HC, Verhaar MC, Braam B, Rabelink TJ, van Zonneveld AJ. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes. 2004; 53: 195–199.CrossrefMedlineGoogle Scholar23 Tanii M, Yonemitsu Y, Fujii T, Shikada Y, Kohno R, Onimaru M, Okano S, Inoue M, Hasegawa M, Onohara T, Maehara Y, Sueishi K Diabetic microangiopathy in ischemic limb is a disease of disturbance of the PDGF-BB/PKC axis, but not of impaired expression of angiogenic factors. Circ Res. 2006; 98: 55–62.LinkGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsCited By Rusdiana R, Widjaja S, Amelia R, Syarifah S and Rusmalawati R (2021) The Role Vascular Endothelial Growth Factor, Control Glycemic, Lipid Profile, and Hypoxia-inducible Factor 1-Alpha at Type 2 Diabetic Patients in North Sumatera, Indonesia, Open Access Macedonian Journal of Medical Sciences, 10.3889/oamjms.2021.7074, 9:B, (1215-1218) Alexandre-Heymann L, Barral M, Dohan A and Larger E (2020) Patients with type 2 diabetes present with multiple anomalies of the pancreatic arterial tree on abdominal computed tomography: comparison between patients with type 2 diabetes and a matched control group, Cardiovascular Diabetology, 10.1186/s12933-020-01098-1, 19:1, Online publication date: 1-Dec-2020. Lazarov O, Minshall R and Bonini M (2020) Harnessing neurogenesis in the adult brain—A role in type 2 diabetes mellitus and Alzheimer's disease Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Treating neurodegenerative diseases as metabolic diseases, 10.1016/bs.irn.2020.03.020, (235-269), . Zhang Q, Fang W, Ma L, Wang Z, Yang Y and Lu Y (2018) VEGF levels in plasma in relation to metabolic control, inflammation, and microvascular complications in type-2 diabetes, Medicine, 10.1097/MD.0000000000010415, 97:15, (e0415), Online publication date: 1-Apr-2018. López-Díez R, Shen X, Daffu G, Khursheed M, Hu J, Song F, Rosario R, Xu Y, Li Q, Xi X, Zou Y, Li H, Schmidt A and Yan S (2017) Ager Deletion Enhances Ischemic Muscle Inflammation, Angiogenesis, and Blood Flow Recovery in Diabetic Mice, Arteriosclerosis, Thrombosis, and Vascular Biology, 37:8, (1536-1547), Online publication date: 1-Aug-2017. Chung S, Choi B, Kim J, Lee Y, Yoon J, Oh K and Park K (2017) Altered Gene and Protein Expressions in Torn Rotator Cuff Tendon Tissues in Diabetic Patients, Arthroscopy: The Journal of Arthroscopic & Related Surgery, 10.1016/j.arthro.2016.08.017, 33:3, (518-526.e1), Online publication date: 1-Mar-2017. Hu W, Zhang Y, Wang L, Lau C, Xu J, Luo J, Gou L, Yao X, Chen Z, Ma R, Tian X and Huang Y (2016) Bone Morphogenic Protein 4-Smad–Induced Upregulation of Platelet-Derived Growth Factor AA Impairs Endothelial Function, Arteriosclerosis, Thrombosis, and Vascular Biology, 36:3, (553-560), Online publication date: 1-Mar-2016. Bonds J, Hart P, Minshall R, Lazarov O, Haus J and Bonini M (2016) Type 2 Diabetes Mellitus as a Risk Factor for Alzheimer's Disease Genes, Environment and Alzheimer's Disease, 10.1016/B978-0-12-802851-3.00013-9, (387-413), . Li W, Nie S, Yao Y, Liu X, Shao D, Gong D, Cui S, Phillips G, He M and Xie M (2015) Ganoderma atrum Polysaccharide Ameliorates Hyperglycemia-Induced Endothelial Cell Death via a Mitochondria-ROS Pathway , Journal of Agricultural and Food Chemistry, 10.1021/acs.jafc.5b03462, 63:37, (8182-8191), Online publication date: 23-Sep-2015. Laviers H and Zambarakji H (2014) Enhanced depth imaging-OCT of the choroid: a review of the current literature, Graefe's Archive for Clinical and Experimental Ophthalmology, 10.1007/s00417-014-2840-y, 252:12, (1871-1883), Online publication date: 1-Dec-2014. Lovati A, Romanò C, Monti L, Vassena C, Previdi S, Drago L and Kates S (2014) Does PGE1 Vasodilator Prevent Orthopaedic Implant-Related Infection in Diabetes? Preliminary Results in a Mouse Model, PLoS ONE, 10.1371/journal.pone.0094758, 9:4, (e94758) Kim B, Ko Y, Kim S, Chung J, Hwang K, Choi D and Jang Y (2013) Suppression of Receptor for Advanced Glycation End Products Improves Angiogenic Responses to Ischemia in Diabetic Mouse Hindlimb Ischemia Model, ISRN Vascular Medicine, 10.1155/2013/908108, 2013, (1-7), Online publication date: 8-Sep-2013. Prakash R, Johnson M, Fagan S, Ergul A and Borlongan C (2013) Cerebral Neovascularization and Remodeling Patterns in Two Different Models of Type 2 Diabetes, PLoS ONE, 10.1371/journal.pone.0056264, 8:2, (e56264) Ergul A, Alhusban A and Fagan S (2012) Angiogenesis, Stroke, 43:8, (2270-2274), Online publication date: 1-Aug-2012. Miteva M and Romanelli P (2012) Histopathology of Wounds Measurements in Wound Healing, 10.1007/978-1-4471-2987-5_9, (155-173), . Dong L, Kang L, Ding L, Chen Q, Bai J, Gu R, Li L and Xu B (2011) Insulin modulates ischemia-induced endothelial progenitor cell mobilization and neovascularization in diabetic mice, Microvascular Research, 10.1016/j.mvr.2011.09.006, 82:3, (227-236), Online publication date: 1-Nov-2011. Fallahzadeh A, Khazaei M and Sharifi M (2011) RESTORATION OF ANGIOGENESIS BY ENALAPRIL IN DIABETIC HINDLIMB ISCHEMC RATS, Biomedical Papers, 10.5507/bp.2011.026, 155:2, (137-142), Online publication date: 1-Jun-2011. Schwartz E, Wicinski B, Schmeidler J, Haroutunian V and Hof P (2010) Cardiovascular risk factors affect hippocampal microvasculature in early AD, Translational Neuroscience, 10.2478/v10134-010-0040-9, 1:4, (292-299), Online publication date: 1-Dec-2010. Mahdy R, Nada W, Hadhoud K and El-Tarhony S (2010) The role of vascular endothelial growth factor in the progression of diabetic vascular complications, Eye, 10.1038/eye.2010.86, 24:10, (1576-1584), Online publication date: 1-Oct-2010. Li W, Prakash R, Kelly-Cobbs A, Ogbi S, Kozak A, El-Remessy A, Schreihofer D, Fagan S and Ergul A (2009) Adaptive Cerebral Neovascularization in a Model of Type 2 Diabetes, Diabetes, 10.2337/db09-0902, 59:1, (228-235), Online publication date: 1-Jan-2010. Huang Y, Marui A, Sakaguchi H, Esaki J, Arai Y, Hirose K, Bir S, Horiuchi H, Maruyama T, Ikeda T, Tabata Y and Komeda M (2008) Sustained Release of Prostaglandin E1 Potentiates the Impaired Therapeutic Angiogenesis by Basic Fibroblast Growth Factor in Diabetic Murine Hindlimb Ischemia, Circulation Journal, 10.1253/circj.CJ-07-0960, 72:10, (1693-1699), . Ergul A, Elgebaly M, Middlemore M, Li W, Elewa H, Switzer J, Hall C, Kozak A and Fagan S (2007) Increased hemorrhagic transformation and altered infarct size and localization after experimental stroke in a rat model type 2 diabetes, BMC Neurology, 10.1186/1471-2377-7-33, 7:1, Online publication date: 1-Dec-2007. Celebiler Cavusoglu A, Bilgili S, Alaluf A, Doğan A, Yılmaz F, Aslanca D, Karaca B, Yüksel B and Topaloglu E (2007) Vascular Endothelial Growth Factor Level in the Serum of Diabetic Patients with Retinopathy, Annals of Ophthalmology, 10.1007/s12009-007-0037-2, 39:3, (205-208), Online publication date: 22-Oct-2007. Tolppanen A, Pulkkinen L, Kolehmainen M, Schwab U, Lindström J, Tuomilehto J and Uusitupa M (2007) Tenomodulin is Associated with Obesity and Diabetes Risk: The Finnish Diabetes Prevention Study*, Obesity, 10.1038/oby.2007.613, 15:5, (1082-1088), Online publication date: 1-May-2007. January 6, 2006Vol 98, Issue 1 Advertisement Article InformationMetrics https://doi.org/10.1161/01.RES.0000200396.90220.41PMID: 16397150 Originally publishedJanuary 6, 2006 KeywordsangiogenesisIschemiadiabetesPDGF-BBPDF download Advertisement
Referência(s)